Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study. - Université de Bretagne Occidentale Accéder directement au contenu
Article Dans Une Revue The European respiratory journal. Supplement. Année : 2017

Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study.

Résumé

We aimed to assess the risk of recurrent venous thromboembolism (VTE) in patients with chronic obstructive pulmonary disease (COPD) following cessation of anticoagulation therapy.In a prospective cohort of 1468 patients with a documented episode of VTE, followed for up to 5 years after cessation of anticoagulation therapy, the diagnosis of COPD was confirmed in 136. The main outcome was recurrent VTE. The secondary outcome was overall mortality. Univariate and multivariate analyses were performed to identify the risk factors of recurrence.Of the 1468 patients included, recurrent VTE was observed in 306 (34 with COPD and 272 without) during a median follow-up period of 36.5 months. The incidence rate of recurrent VTE was 9.1% (95% CI 6.5-12.8) for COPD patients and 7.0% (95% CI 6.2-7.9) for non-COPD patients. COPD was not associated with an increased risk of VTE recurrence on univariate or multivariate analyses (hazard ratio: 1.0 (95% CI 0.7-1.4)). The risk of death, adjusted for demographic and clinical characteristics, showed no increase in COPD patients, as compared to non-COPD patients.In patients with COPD who had an acute episode of VTE, the risk of recurrent VTE was not any higher than that in non-COPD patients.
Fichier non déposé

Dates et versions

hal-01573421 , version 1 (09-08-2017)

Identifiants

  • HAL Id : hal-01573421 , version 1
  • PUBMED : 28751412

Citer

Raphael Le Mao, Cécile Tromeur, Amélie Bazire, Maelenn Gouillou, Marie Guegan, et al.. Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study.. The European respiratory journal. Supplement., 2017, 50 (1). ⟨hal-01573421⟩
140 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More